{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Cancer&page=66",
    "query": {
      "condition": "Metastatic Solid Cancer",
      "page": 66
    },
    "page_size": 10
  },
  "pagination": {
    "page": 66,
    "page_size": 10,
    "total_count": 1765,
    "total_pages": 177,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Cancer&page=67&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Cancer&page=65&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T19:27:50.086Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06669117",
      "title": "FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "MET Alteration"
      ],
      "interventions": [
        {
          "name": "VERT-002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pierre Fabre Medicament",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2024-10-22",
      "completion_date": "2032-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-11-17T19:27:50.086Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Canton, Ohio • Nashville, Tennessee",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06669117"
    },
    {
      "nct_id": "NCT05061940",
      "title": "This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer",
        "Melanoma",
        "HPV-Related Malignancy",
        "HPV-Related Carcinoma",
        "HPV-Related Cervical Carcinoma",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "Lung Cancer, Nonsmall Cell",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "Tumor Profiling",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Repertoire Immune Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2021-05-05",
      "completion_date": "2022-10-11",
      "has_results": false,
      "last_update_posted_date": "2022-12-06",
      "last_synced_at": "2026-11-17T19:27:50.086Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Ann Arbor, Michigan • Nashville, Tennessee",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05061940"
    },
    {
      "nct_id": "NCT00731861",
      "title": "Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm Metastasis",
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "Paclitaxel plus PTK787",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2005-05",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2014-09-11",
      "last_synced_at": "2026-11-17T19:27:50.086Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00731861"
    },
    {
      "nct_id": "NCT04424641",
      "title": "A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Solid Tumor(s)",
        "Prostate Cancer",
        "Esophageal Cancer",
        "Triple Negative Breast Cancer (TNBC)",
        "Squamous Cell Carcinoma of Head and Neck (SCCHN)",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Bladder Cancer",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-07-15",
      "completion_date": "2021-10-29",
      "has_results": true,
      "last_update_posted_date": "2023-07-25",
      "last_synced_at": "2026-11-17T19:27:50.086Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04424641"
    },
    {
      "nct_id": "NCT07524322",
      "title": "Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "PIK3CA Mutation",
        "HER2- Negative Breast Cancer",
        "Advanced Breast Cancer",
        "Unresectable Solid Tumor",
        "Hormone Receptor Positive Tumor",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "RGT-490",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regor Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2026-07-21",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-17T19:27:50.086Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Pittsburgh, Pennsylvania • Houston, Texas + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07524322"
    },
    {
      "nct_id": "NCT01576666",
      "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dose Escalation",
        "Safety",
        "Preliminary Efficacy",
        "Advanced Solid Tumors",
        "Metastatic Breast Cancer",
        "Advanced Pancreatic Adenocarcinoma",
        "Metastatic Colorectal Cancer",
        "Recurrent Glioblastoma Multiforme",
        "Gastric Cancer",
        "Gastroesophageal Junction Cancer",
        "Triple Negative Metastatic Breast Cancer",
        "Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "LDE225",
          "type": "DRUG"
        },
        {
          "name": "BKM120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2012-07",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-11-17T19:27:50.086Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01576666"
    },
    {
      "nct_id": "NCT01665183",
      "title": "Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ADI-PEG 20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Polaris Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2012-09",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-02-25",
      "last_synced_at": "2026-11-17T19:27:50.086Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01665183"
    },
    {
      "nct_id": "NCT01355302",
      "title": "E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Previously Untreated Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "E7050",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2011-11",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-11-17T19:27:50.086Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Plantation, Florida • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01355302"
    },
    {
      "nct_id": "NCT00390052",
      "title": "3-AP in Treating Patients With Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "triapine",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2006-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-16",
      "last_synced_at": "2026-11-17T19:27:50.086Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00390052"
    },
    {
      "nct_id": "NCT05678998",
      "title": "WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "WTX-330",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Werewolf Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2022-12-06",
      "completion_date": "2025-02-05",
      "has_results": true,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-11-17T19:27:50.086Z",
      "location_count": 9,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05678998"
    }
  ]
}